Barclays’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.41M | Sell |
2,617,969
-462,610
| -15% | -$560K | ﹤0.01% | 2234 |
|
|
2025
Q4 | $3.94M | Sell |
3,080,579
-94,055
| -3% | -$126K | ﹤0.01% | 2404 |
|
|
2025
Q3 | $4.13M | Sell |
3,174,634
-131,741
| -4% | -$173K | ﹤0.01% | 2348 |
|
|
2025
Q2 | $3.97M | Buy |
3,306,375
+205,836
| +7% | +$228K | ﹤0.01% | 2318 |
|
|
2025
Q1 | $3.35M | Sell |
3,100,539
-130,312
| -4% | -$183K | ﹤0.01% | 2236 |
|
|
2024
Q4 | $5.65M | Buy |
3,230,851
+2,491
| +0.1% | +$4.64K | ﹤0.01% | 2040 |
|
|
2024
Q3 | $6.23M | Buy |
3,228,360
+377,195
| +13% | +$739K | ﹤0.01% | 1890 |
|
|
2024
Q2 | $5.05M | Sell |
2,851,165
-1,102,655
| -28% | -$2.7M | ﹤0.01% | 1529 |
|
|
2024
Q1 | $10.7M | Buy |
3,953,820
+3,790,428
| +2,320% | +$9.15M | ﹤0.01% | 1339 |
|
|
2023
Q4 | $361K | Buy |
163,392
+115,198
| +239% | +$246K | ﹤0.01% | 4084 |
|
|
2023
Q3 | $140K | Buy |
+48,194
| New | +$126K | ﹤0.01% | 3454 |
|
|
2023
Q2 | – | Sell |
-27,385
| Closed | -$53.4K | – | 4826 |
|
|
2023
Q1 | $53.4K | Buy |
+27,385
| New | +$54.1K | ﹤0.01% | 4428 |
|
|
2022
Q3 | – | Sell |
-210
| Closed | – | – | 4982 |
|
|
2022
Q2 | $0 | Sell |
210
-12,497
| -98% | -$30.9K | ﹤0.01% | 5158 |
|
|
2022
Q1 | $45K | Sell |
12,707
-79,770
| -86% | -$276K | ﹤0.01% | 4156 |
|
|
2021
Q4 | $362K | Buy |
92,477
+61,341
| +197% | +$287K | ﹤0.01% | 3338 |
|
|
2021
Q3 | $205K | Buy |
31,136
+21,535
| +224% | +$142K | ﹤0.01% | 3611 |
|
|
2021
Q2 | $60K | Sell |
9,601
-52,254
| -84% | -$279K | ﹤0.01% | 4055 |
|
|
2021
Q1 | $279K | Buy |
61,855
+37,970
| +159% | +$209K | ﹤0.01% | 3543 |
|
|
2020
Q4 | $144K | Sell |
23,885
-95,692
| -80% | -$629K | ﹤0.01% | 3956 |
|
|
2020
Q3 | $888K | Buy |
119,577
+1,921
| +2% | +$13.3K | ﹤0.01% | 2794 |
|
|
2020
Q2 | $472K | Sell |
117,656
-8,191
| -7% | -$28.5K | ﹤0.01% | 3385 |
|
|
2020
Q1 | $319K | Buy |
125,847
+56,572
| +82% | +$186K | ﹤0.01% | 3944 |
|
|
2019
Q4 | $241K | Buy |
69,275
+19,077
| +38% | +$67.1K | ﹤0.01% | 4892 |
|
|
2019
Q3 | $233K | Buy |
50,198
+2,645
| +6% | +$20.8K | ﹤0.01% | 4856 |
|
|
2019
Q2 | $586K | Buy |
47,553
+16,821
| +55% | +$214K | ﹤0.01% | 4185 |
|
|
2019
Q1 | $408K | Buy |
30,732
+30,685
| +65,287% | +$323K | ﹤0.01% | 4295 |
|
|
2018
Q4 | $0 | Sell |
47
-50,633
| -100% | -$394K | ﹤0.01% | 7136 |
|
|
2018
Q3 | $380K | Buy |
50,680
+47,250
| +1,378% | +$336K | ﹤0.01% | 4495 |
|
|
2018
Q2 | $21K | Sell |
3,430
-7,483
| -69% | -$42.6K | ﹤0.01% | 6155 |
|
|
2018
Q1 | $63K | Buy |
10,913
+4,763
| +77% | +$31.3K | ﹤0.01% | 5723 |
|
|
2017
Q4 | $36K | Buy |
6,150
+4,427
| +257% | +$24.2K | ﹤0.01% | 5948 |
|
|
2017
Q3 | $8K | Sell |
1,723
-12,979
| -88% | -$54.6K | ﹤0.01% | 6230 |
|
|
2017
Q2 | $60K | Buy |
14,702
+14,345
| +4,018% | +$68K | ﹤0.01% | 5239 |
|
|
2017
Q1 | $2K | Sell |
357
-790
| -69% | -$5.01K | ﹤0.01% | 6482 |
|
|
2016
Q4 | $8K | Sell |
1,147
-5,590
| -83% | -$35.1K | ﹤0.01% | 5981 |
|
|
2016
Q3 | $54K | Buy |
+6,737
| New | +$61.9K | ﹤0.01% | 4926 |
|
|
2016
Q2 | – | Sell |
-1,853
| Closed | -$15K | – | 6472 |
|
|
2016
Q1 | $15K | Buy |
+1,853
| New | +$13.4K | ﹤0.01% | 5338 |
|
|
2015
Q4 | – | Sell |
-150
| Closed | -$1K | – | 6287 |
|
|
2015
Q3 | $1K | Sell |
150
-402
| -73% | -$6.33K | ﹤0.01% | 6550 |
|
|
2015
Q2 | $13K | Sell |
552
-288
| -34% | -$9.09K | ﹤0.01% | 5941 |
|
|
2015
Q1 | $35K | Sell |
840
-1,439
| -63% | -$56.9K | ﹤0.01% | 5515 |
|
|
2014
Q4 | $75K | Sell |
2,279
-2,792
| -55% | -$79.1K | ﹤0.01% | 5406 |
|
|
2014
Q3 | $121K | Sell |
5,071
-18,932
| -79% | -$532K | ﹤0.01% | 5184 |
|
|
2014
Q2 | $696K | Buy |
24,003
+22,691
| +1,729% | +$727K | ﹤0.01% | 3670 |
|
|
2014
Q1 | $58K | Buy |
1,312
+707
| +117% | +$31.1K | ﹤0.01% | 5881 |
|
|
2013
Q4 | $23K | Sell |
605
-345
| -36% | -$10.2K | ﹤0.01% | 6628 |
|
|
2013
Q3 | $20K | Sell |
950
-362
| -28% | -$7.11K | ﹤0.01% | 6531 |
|
|
2013
Q2 | $23K | Buy |
+1,312
| New | +$23K | ﹤0.01% | 6768 |
|
Other funds holding LAB
CC
MCO
LFCM
VCM
HBWM
Barclays's LAB Position: Q1 2026 in Review
Barclays reduced its Standard BioTools (LAB) stake by 15% in Q1 2026, selling an estimated $560K and leaving 2,617,969 shares worth $2.41M. The position accounts for ﹤0.01% of the portfolio, ranked #2234.
Barclays first reported a position in LAB in Q2 2013 and has held it in 47 quarters since. The position peaked at $10.7M in Q1 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.
- Barclays held 2,617,969 shares of Standard BioTools worth $2.41M as of Q1 2026.
- Barclays sold 462,610 Standard BioTools shares in Q1 2026, an estimated $560K.
- Standard BioTools made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2234 holding.
- Barclays first reported a position in Standard BioTools in Q2 2013 and has held it in 47 quarters since.
- Barclays's Standard BioTools position peaked at $10.7M in Q1 2024.
- 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.